Drug Trial Radar · NCT02045797
Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Last checked: Nov 20, 2026Latest source record: Nov 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Mar 24, 2014
Primary completion
Jun 29, 2015
Study completion Jun 29, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GSK2140944 belongs to a novel structural class of antibiotics - Bacterial Type II Topoisomerase Inhibitors (BTI). This is a Phase II, randomized, two-part, multicenter study designed to select the optimal dose by further characterizing the safety, tolerability and PK of GSK 2140944 and by evaluating efficacy in subjects requiring in-patient medical care to treat their suspected or confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSI). The selected dose will be used in future studies.
Conditions
- Infections, Bacterial
Interventions
GSK2140944 LyophileDrug
GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
GSK2140944 CapsulesDrug
GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal RateTime frame: Up to Day 3
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
La Mesa, California
GSK Investigational Site
Oceanside, California
GSK Investigational Site
Sylmar, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Miramar, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Council Bluffs, Iowa
GSK Investigational Site
Hazard, Kentucky
GSK Investigational Site
Zachary, Louisiana
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Carriere, Mississippi
GSK Investigational Site
Jackson, Mississippi
GSK Investigational Site
Butte, Montana
GSK Investigational Site
Lincoln, Nebraska
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Belleville, New Jersey
GSK Investigational Site
Neptune City, New Jersey
GSK Investigational Site
Albany, New York
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Lima, Ohio
GSK Investigational Site
Toledo, Ohio
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Channelview, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.